BDSX - Biodesix gains on peer reviewed data from trial for lung cancer test
2023-07-12 09:27:52 ET
Biodesix ( NASDAQ: BDSX ) jumped ~10% in the pre-market trading Wednesday after announcing that the science journal PLOS ONE published data from its ORACLE study, which returned positive results for the company’s Nodify XL2 Test designed for early detection of lung cancer.
According to the data published last week, the real-world study reached the primary endpoint with those who received the Nodify XL2 test, indicating a statistically significant decline in the need for unnecessary invasive procedures for benign lung nodules.
Biodesix ( BDSX ) highlighted the utility of Nodify XL2, noting that while lung nodules allow for early detection of lung cancer, unnecessary invasive procedures are common because up to 95% of lung nodules are benign.
In the ORACLE study, patients managed with Nodify XL2 were 74% less likely to undergo an invasive procedure compared to those in the control group, the company said.
The investigators also found no difference between Nodify XL2 and the control groups in terms of the percentage of patients sent for CT scanning for cancer nodules.
More on Biodesix
For further details see:
Biodesix gains on peer reviewed data from trial for lung cancer test